{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T04:21:59Z","timestamp":1776140519501,"version":"3.50.1"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>The expression level of \u03b1-synuclein is thought to play a crucial role in the pathogenesis of Parkinson\u2019s disease. However, little is known about the molecular mechanisms regulating the transcription of its gene, <jats:italic>SNCA<\/jats:italic>, particularly in the context of the disease. The transcription factor ZSCAN21 has been shown to act on <jats:italic>SNCA<\/jats:italic>, but whether ZSCAN21 is actually involved in the induction of <jats:italic>SNCA<\/jats:italic> transcription in Parkinson\u2019s disease is unknown. To address this question, we used the MPTP mouse model and LUHMES-derived dopaminergic neuronal spheroids, subjected to Parkinson\u2019s disease-related neurotoxins and mutations. We show that MPP<jats:sup>+<\/jats:sup>-treated spheroids recapitulate the main features of \u03b1-synuclein pathology and that MPP<jats:sup>+<\/jats:sup>-triggered transcriptional induction of <jats:italic>SNCA<\/jats:italic> is associated with ZSCAN21 stabilisation. Importantly, knock-down of ZSCAN21 prevents both the MPP<jats:sup>+<\/jats:sup>-triggered increase in \u03b1-synuclein mRNA and pre-mRNA levels in LUHMES-derived spheroids and the death of dopaminergic neurons in the <jats:italic>substantia nigra<\/jats:italic> of MPTP-treated mice. These effects are recapitulated by knockdown of TRIM17, a ZSCAN21 stabiliser which prevents its ubiquitination and degradation mediated by TRIM41. Moreover, reducing the interaction between ZSCAN21 and TRIM41, either by inserting Parkinson\u2019s disease-associated mutations into the <jats:italic>TRIM41<\/jats:italic> gene or by preventing SUMOylation of ZSCAN21, results in both stabilisation of ZSCAN21 and induction of <jats:italic>SNCA<\/jats:italic>. Taken together, our data strongly suggest that ZSCAN21 is a crucial transcription factor for pathogenic \u03b1-synuclein expression and neurodegeneration in Parkinson\u2019s disease, pointing to its regulators, TRIM17 and TRIM41, as original therapeutic targets for a neuroprotective treatment of Parkinson\u2019s disease.<\/jats:p>","DOI":"10.1038\/s41419-025-07722-w","type":"journal-article","created":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T16:40:52Z","timestamp":1747413652000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["ZSCAN21 mediates the pathogenic transcriptional induction of \u03b1-synuclein in cellular and animal models of Parkinson\u2019s disease"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7937-3701","authenticated-orcid":false,"given":"Alina","family":"Kozoriz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9818-1695","authenticated-orcid":false,"given":"St\u00e9phan","family":"Mora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria-Alessandra","family":"Damiano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iria","family":"Carballo-Carbajal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6195-812X","authenticated-orcid":false,"given":"Annabelle","family":"Parent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8993-3565","authenticated-orcid":false,"given":"Lorena","family":"Kumarasinghe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1352-989X","authenticated-orcid":false,"given":"Miquel","family":"Vila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7059-7963","authenticated-orcid":false,"given":"Ir\u00e9na","family":"Lassot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3735-7527","authenticated-orcid":false,"given":"Solange","family":"Desagher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,16]]},"reference":[{"key":"7722_CR1","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.3233\/JPD-181474","volume":"8","author":"ER Dorsey","year":"2018","unstructured":"Dorsey ER, Sherer T, Okun MS, Bloem BR. The emerging evidence of the Parkinson pandemic. J Parkinsons Dis. 2018;8:S3\u2013S8.","journal-title":"J Parkinsons Dis"},{"key":"7722_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.13","volume":"3","author":"W Poewe","year":"2017","unstructured":"Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, et al. Parkinson disease. Nat Rev Dis Prim. 2017;3:17013.","journal-title":"Nat Rev Dis Prim"},{"key":"7722_CR3","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/S1474-4422(19)30287-X","volume":"19","author":"C Blauwendraat","year":"2020","unstructured":"Blauwendraat C, Nalls MA, Singleton AB. The genetic architecture of Parkinson\u2019s disease. Lancet Neurol. 2020;19:170\u20138.","journal-title":"Lancet Neurol"},{"key":"7722_CR4","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1126\/science.276.5321.2045","volume":"276","author":"MH Polymeropoulos","year":"1997","unstructured":"Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson\u2019s disease. Science. 1997;276:2045\u20137.","journal-title":"Science"},{"key":"7722_CR5","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.neuint.2017.12.011","volume":"119","author":"H Mochizuki","year":"2018","unstructured":"Mochizuki H, Choong CJ, Masliah E. A refined concept: alpha-synuclein dysregulation disease. Neurochem Int. 2018;119:84\u201396.","journal-title":"Neurochem Int"},{"key":"7722_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.559791","volume":"8","author":"M Fouka","year":"2020","unstructured":"Fouka M, Mavroeidi P, Tsaka G, Xilouri M. In search of effective treatments targeting \u03b1-synuclein toxicity in synucleinopathies: pros and cons. Front Cell Dev Biol. 2020;8:559791.","journal-title":"Front Cell Dev Biol"},{"key":"7722_CR7","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.tins.2022.11.007","volume":"46","author":"M Sharma","year":"2023","unstructured":"Sharma M, Burr\u00e9 J. \u03b1-Synuclein in synaptic function and dysfunction. Trends Neurosci. 2023;46:153\u201366.","journal-title":"Trends Neurosci"},{"key":"7722_CR8","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/42166","volume":"388","author":"MG Spillantini","year":"1997","unstructured":"Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature. 1997;388:839\u201340.","journal-title":"Nature"},{"key":"7722_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nm.4269","volume":"23","author":"YC Wong","year":"2017","unstructured":"Wong YC, Krainc D. alpha-synuclein toxicity in neurodegeneration: mechanism and therapeutic strategies. Nat Med. 2017;23:1\u201313.","journal-title":"Nat Med"},{"key":"7722_CR10","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.conb.2022.01.003","volume":"72","author":"NP Marotta","year":"2022","unstructured":"Marotta NP, Lee VM-Y. Modeling the cellular fate of alpha-synuclein aggregates: a pathway to pathology. Curr Opin Neurobiol. 2022;72:171\u20137.","journal-title":"Curr Opin Neurobiol"},{"key":"7722_CR11","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s10048-016-0478-0","volume":"17","author":"L Tagliafierro","year":"2016","unstructured":"Tagliafierro L, Chiba-Falek O. Up-regulation of SNCA gene expression: implications to synucleinopathies. Neurogenetics. 2016;17:145\u201357.","journal-title":"Neurogenetics"},{"key":"7722_CR12","doi-asserted-by":"publisher","first-page":"199","DOI":"10.3389\/fnins.2018.00199","volume":"12","author":"DA Piper","year":"2018","unstructured":"Piper DA, Sastre D, Sch\u00fcle B. Advancing stem cell models of alpha-synuclein gene regulation in neurodegenerative disease. Front Neurosci. 2018;12:199.","journal-title":"Front Neurosci"},{"key":"7722_CR13","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/bs.pbr.2020.01.002","volume":"252","author":"RG Langston","year":"2020","unstructured":"Langston RG, Cookson MR. Pathways of protein synthesis and degradation in PD pathogenesis. Prog Brain Res. 2020;252:217\u201370.","journal-title":"Prog Brain Res"},{"key":"7722_CR14","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s00439-016-1749-4","volume":"136","author":"V La Cognata","year":"2017","unstructured":"La Cognata V, Morello G, D\u2019Agata V, Cavallaro S. Copy number variability in Parkinson\u2019s disease: assembling the puzzle through a systems biology approach. Hum Genet. 2017;136:13\u201337.","journal-title":"Hum Genet"},{"key":"7722_CR15","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s10048-018-0546-8","volume":"19","author":"A Afek","year":"2018","unstructured":"Afek A, Tagliafierro L, Glenn OC, Lukatsky DB, Gordan R, Chiba-Falek O. Toward deciphering the mechanistic role of variations in the Rep1 repeat site in the transcription regulation of SNCA gene. Neurogenetics. 2018;19:135\u201344.","journal-title":"Neurogenetics"},{"key":"7722_CR16","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1002\/ana.25274","volume":"84","author":"L Pihlstr\u00f8m","year":"2018","unstructured":"Pihlstr\u00f8m L, Blauwendraat C, Cappelletti C, Berge-Seidl V, Langmyhr M, Henriksen SP, et al. A comprehensive analysis of SNCA-related genetic risk in sporadic parkinson disease. Ann Neurol. 2018;84:117\u201329.","journal-title":"Ann Neurol"},{"key":"7722_CR17","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1096\/fj.07-9348com","volume":"22","author":"J Fuchs","year":"2008","unstructured":"Fuchs J, Tichopad A, Golub Y, Munz M, Schweitzer KJ, Wolf B, et al. Genetic variability in the SNCA gene influences alpha-synuclein levels in the blood and brain. FASEB J. 2008;22:1327\u201334.","journal-title":"FASEB J"},{"key":"7722_CR18","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1093\/hmg\/ddl030","volume":"15","author":"I Mizuta","year":"2006","unstructured":"Mizuta I, Satake W, Nakabayashi Y, Ito C, Suzuki S, Momose Y, et al. Multiple candidate gene analysis identifies alpha-synuclein as a susceptibility gene for sporadic Parkinson\u2019s disease. Hum Mol Genet. 2006;15:1151\u20138.","journal-title":"Hum Mol Genet"},{"key":"7722_CR19","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/nature17939","volume":"533","author":"F Soldner","year":"2016","unstructured":"Soldner F, Stelzer Y, Shivalila CS, Abraham BJ, Latourelle JC, Barrasa MI, et al. Parkinson-associated risk variant in distal enhancer of alpha-synuclein modulates target gene expression. Nature. 2016;533:95\u20139.","journal-title":"Nature"},{"key":"7722_CR20","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1016\/j.celrep.2018.11.002","volume":"25","author":"I Lassot","year":"2018","unstructured":"Lassot I, Mora S, Lesage S, Zieba BA, Coque E, Condroyer C. et al. The E3 Ubiquitin Ligases TRIM17 and TRIM41 modulate \u03b1-synuclein expression by regulating ZSCAN21. Cell Rep. 2018;25:2484\u201396.e9.","journal-title":"Cell Rep"},{"key":"7722_CR21","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1046\/j.1471-4159.2000.740721.x","volume":"74","author":"M Vila","year":"2000","unstructured":"Vila M, Vukosavic S, Jackson-Lewis V, Neystat M, Jakowec M, Przedborski S. Alpha-synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the parkinsonian toxin MPTP. J Neurochem. 2000;74:721\u20139.","journal-title":"J Neurochem"},{"key":"7722_CR22","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1289\/ehp.1002839","volume":"119","author":"CM Tanner","year":"2011","unstructured":"Tanner CM, Kamel F, Ross GW, Hoppin JA, Goldman SM, Korell M, et al. Rotenone, paraquat, and Parkinson\u2019s Disease. Environmental Health Perspect. 2011;119:866\u201372.","journal-title":"Environmental Health Perspect"},{"key":"7722_CR23","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.pneurobio.2017.04.004","volume":"154","author":"S Guhathakurta","year":"2017","unstructured":"Guhathakurta S, Bok E, Evangelista BA, Kim Y-S. Deregulation of \u03b1-synuclein in Parkinson\u2019s disease: Insight from epigenetic structure and transcriptional regulation of SNCA. Prog Neurobiol. 2017;154:21\u201336.","journal-title":"Prog Neurobiol"},{"key":"7722_CR24","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.neulet.2015.05.029","volume":"599","author":"S Brenner","year":"2015","unstructured":"Brenner S, Wersinger C, Gasser T. Transcriptional regulation of the alpha-synuclein gene in human brain tissue. Neurosci Lett. 2015;599:140\u20135.","journal-title":"Neurosci Lett"},{"key":"7722_CR25","doi-asserted-by":"publisher","first-page":"8756","DOI":"10.1074\/jbc.M115.704973","volume":"291","author":"G Dermentzaki","year":"2016","unstructured":"Dermentzaki G, Paschalidis N, Politis PK, Stefanis L. Complex Effects of the ZSCAN21 transcription Factor on transcriptional regulation of alpha-synuclein in primary neuronal cultures and in vivo. J Biol Chem. 2016;291:8756\u201372.","journal-title":"J Biol Chem"},{"key":"7722_CR26","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202101426","volume":"8","author":"L Bai","year":"2021","unstructured":"Bai L, Yang G, Qin Z, Lyu J, Wang Y, Feng J, et al. Proteome-wide profiling of readers for DNA modification. Adv Sci. 2021;8:e2101426.","journal-title":"Adv Sci"},{"key":"7722_CR27","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1111\/j.1471-4159.2009.06250.x","volume":"110","author":"RL Clough","year":"2009","unstructured":"Clough RL, Dermentzaki G, Stefanis L. Functional dissection of the alpha-synuclein promoter: transcriptional regulation by ZSCAN21 and ZNF219. J Neurochem. 2009;110:1479\u201390.","journal-title":"J Neurochem"},{"key":"7722_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.gene.2005.06.022","volume":"359","author":"LC Edelstein","year":"2005","unstructured":"Edelstein LC, Collins T. The SCAN domain family of zinc finger transcription factors. Gene. 2005;359:1\u201317.","journal-title":"Gene"},{"key":"7722_CR29","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1242\/dev.122.2.555","volume":"122","author":"XW Yang","year":"1996","unstructured":"Yang XW, Zhong R, Heintz N. Granule cell specification in the developing mouse brain as defined by expression of the zinc finger transcription factor RU49. Development. 1996;122:555\u201366.","journal-title":"Development"},{"key":"7722_CR30","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13024-021-00455-2","volume":"16","author":"A Gialluisi","year":"2021","unstructured":"Gialluisi A, Reccia MG, Modugno N, Nutile T, Lombardi A, Di Giovannantonio LG, et al. Identification of sixteen novel candidate genes for late onset Parkinson\u2019s disease. Mol Neurodegener. 2021;16:35.","journal-title":"Mol Neurodegener"},{"key":"7722_CR31","doi-asserted-by":"publisher","first-page":"6329","DOI":"10.1523\/JNEUROSCI.1746-05.2005","volume":"25","author":"J Lotharius","year":"2005","unstructured":"Lotharius J, Falsig J, van Beek J, Payne S, Dringen R, Brundin P, et al. Progressive degeneration of human mesencephalic neuron-derived cells triggered by dopamine-dependent oxidative stress is dependent on the mixed-lineage kinase pathway. J Neurosci. 2005;25:6329\u201342.","journal-title":"J Neurosci"},{"key":"7722_CR32","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1111\/j.1471-4159.2011.07255.x","volume":"119","author":"D Scholz","year":"2011","unstructured":"Scholz D, Poltl D, Genewsky A, Weng M, Waldmann T, Schildknecht S, et al. Rapid, complete and large-scale generation of post-mitotic neurons from the human LUHMES cell line. J Neurochem. 2011;119:957\u201371.","journal-title":"J Neurochem"},{"key":"7722_CR33","doi-asserted-by":"publisher","first-page":"2725","DOI":"10.1007\/s00204-015-1637-z","volume":"90","author":"L Smirnova","year":"2016","unstructured":"Smirnova L, Harris G, Delp J, Valadares M, Pamies D, Hogberg HT, et al. A LUHMES 3D dopaminergic neuronal model for neurotoxicity testing allowing long-term exposure and cellular resilience analysis. Arch Toxicol. 2016;90:2725\u201343.","journal-title":"Arch Toxicol"},{"key":"7722_CR34","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1038\/cdd.2010.73","volume":"17","author":"I Lassot","year":"2010","unstructured":"Lassot I, Robbins I, Kristiansen M, Rahmeh R, Jaudon F, Magiera MM, et al. Trim17, a novel E3 ubiquitin-ligase, initiates neuronal apoptosis. Cell Death Differ. 2010;17:1928\u201341.","journal-title":"Cell Death Differ"},{"key":"7722_CR35","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1038\/s41418-018-0169-5","volume":"26","author":"L Lionnard","year":"2019","unstructured":"Lionnard L, Duc P, Brennan MS, Kueh AJ, Pal M, Guardia F, et al. TRIM17 and TRIM28 antagonistically regulate the ubiquitination and anti-apoptotic activity of BCL2A1. Cell Death Differ. 2019;26:902\u201317.","journal-title":"Cell Death Differ"},{"key":"7722_CR36","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/s41586-020-2493-4","volume":"583","author":"JE Moore","year":"2020","unstructured":"ENCODE Project Consortium, Moore JE, Purcaro MJ, Pratt HE, Epstein CB, Shoresh N, et al. Expanded encyclopaedias of DNA elements in the human and mouse genomes. Nature. 2020;583:699\u2013710.","journal-title":"Nature"},{"key":"7722_CR37","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ymeth.2017.04.003","volume":"121-2","author":"MA DeWitt","year":"2017","unstructured":"DeWitt MA, Corn JE, Carroll D. Genome editing via delivery of Cas9 ribonucleoprotein. Methods. 2017;121-2:9\u201315.","journal-title":"Methods"},{"key":"7722_CR38","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1038\/nbt.3481","volume":"34","author":"CD Richardson","year":"2016","unstructured":"Richardson CD, Ray GJ, DeWitt MA, Curie GL, Corn JE. Enhancing homology-directed genome editing by catalytically active and inactive CRISPR-Cas9 using asymmetric donor DNA. Nat Biotechnol. 2016;34:339\u201344.","journal-title":"Nat Biotechnol"},{"key":"7722_CR39","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1016\/j.celrep.2016.02.018","volume":"14","author":"JB Renaud","year":"2016","unstructured":"Renaud JB, Boix C, Charpentier M, De Cian A, Cochennec J, Duvernois-Berthet E, et al. Improved genome editing efficiency and flexibility using modified oligonucleotides with TALEN and CRISPR-Cas9 nucleases. Cell Rep. 2016;14:2263\u201372.","journal-title":"Cell Rep"},{"key":"7722_CR40","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1002\/iub.580","volume":"64","author":"LM Napolitano","year":"2012","unstructured":"Napolitano LM, Meroni G. TRIM family: pleiotropy and diversification through homomultimer and heteromultimer formation. IUBMB Life. 2012;64:64\u201371.","journal-title":"IUBMB Life"},{"key":"7722_CR41","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/cdd.2014.141","volume":"22","author":"B Mojsa","year":"2015","unstructured":"Mojsa B, Mora S, Bossowski JP, Lassot I, Desagher S. Control of neuronal apoptosis by reciprocal regulation of NFATc3 and Trim17. Cell Death Differ. 2015;22:274\u201386.","journal-title":"Cell Death Differ"},{"key":"7722_CR42","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1038\/s41418-022-01002-2","volume":"29","author":"M Basu-Shrivastava","year":"2022","unstructured":"Basu-Shrivastava M, Mojsa B, Mora S, Robbins I, Bossis G, Lassot I, et al. Trim39 regulates neuronal apoptosis by acting as a SUMO-targeted E3 ubiquitin-ligase for the transcription factor NFATc3. Cell Death Differ. 2022;29:2107\u201322.","journal-title":"Cell Death Differ"},{"key":"7722_CR43","doi-asserted-by":"publisher","first-page":"3483","DOI":"10.1093\/bioinformatics\/btv403","volume":"31","author":"G Beauclair","year":"2015","unstructured":"Beauclair G, Bridier-Nahmias A, Zagury J-F, Sa\u00efb A, Zamborlini A. JASSA: a comprehensive tool for prediction of SUMOylation sites and SIMs. Bioinformatics. 2015;31:3483\u201391.","journal-title":"Bioinformatics"},{"key":"7722_CR44","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nsmb.3366","volume":"24","author":"IA Hendriks","year":"2017","unstructured":"Hendriks IA, Lyon D, Young C, Jensen LJ, Vertegaal ACO, Nielsen ML. Site-specific mapping of the human SUMO proteome reveals co-modification with phosphorylation. Nat Struct Mol Biol. 2017;24:325\u201336.","journal-title":"Nat Struct Mol Biol"},{"key":"7722_CR45","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aba7791","volume":"13","author":"ES Lightcap","year":"2021","unstructured":"Lightcap ES, Yu P, Grossman S, Song K, Khattar M, Xega K, et al. A small-molecule SUMOylation inhibitor activates antitumor immune responses and potentiates immune therapies in preclinical models. Sci Transl Med. 2021;13:eaba7791.","journal-title":"Sci Transl Med"},{"key":"7722_CR46","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.mcn.2013.09.002","volume":"57","author":"JA Wright","year":"2013","unstructured":"Wright JA, McHugh PC, Pan S, Cunningham A, Brown DR. Counter-regulation of alpha- and beta-synuclein expression at the transcriptional level. Mol Cell Neurosci. 2013;57:33\u201341.","journal-title":"Mol Cell Neurosci"},{"key":"7722_CR47","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abq6324","volume":"8","author":"F Cheng","year":"2022","unstructured":"Cheng F, Zheng W, Liu C, Barbuti PA, Yu-Taeger L, Casadei N, et al. Intronic enhancers of the human SNCA gene predominantly regulate its expression in brain in vivo. Sci Adv. 2022;8:eabq6324.","journal-title":"Sci Adv"},{"key":"7722_CR48","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13024-021-00450-7","volume":"16","author":"L Toker","year":"2021","unstructured":"Toker L, Tran GT, Sundaresan J, Tysnes O-B, Alves G, Haugarvoll K, et al. Genome-wide histone acetylation analysis reveals altered transcriptional regulation in the Parkinson\u2019s disease brain. Mol Neurodegener. 2021;16:31.","journal-title":"Mol Neurodegener"},{"key":"7722_CR49","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/ncb748","volume":"4","author":"H Fujiwara","year":"2002","unstructured":"Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, Goldberg MS, et al. alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol. 2002;4:160\u20134.","journal-title":"Nat Cell Biol"},{"key":"7722_CR50","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.tips.2017.03.010","volume":"38","author":"S Schildknecht","year":"2017","unstructured":"Schildknecht S, Monte DAD, Pape R, Tieu K, Leist M. Tipping points and endogenous determinants of nigrostriatal degeneration by MPTP. Trends Pharmacol Sci. 2017;38:541\u201355.","journal-title":"Trends Pharmacol Sci"},{"key":"7722_CR51","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/S0140-6736(89)92366-0","volume":"1","author":"AH Schapira","year":"1989","unstructured":"Schapira AH, Cooper JM, Dexter D, Jenner P, Clark JB, Marsden CD. Mitochondrial complex I deficiency in Parkinson\u2019s disease. Lancet. 1989;1:1269.","journal-title":"Lancet"},{"key":"7722_CR52","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1177\/1073858415574600","volume":"22","author":"S Franco-Iborra","year":"2016","unstructured":"Franco-Iborra S, Vila M, Perier C. The Parkinson disease mitochondrial hypothesis: Where are we at?. Neuroscientist. 2016;22:266\u201377.","journal-title":"Neuroscientist"},{"key":"7722_CR53","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.nbd.2005.08.018","volume":"21","author":"P Klivenyi","year":"2006","unstructured":"Klivenyi P, Siwek D, Gardian G, Yang L, Starkov A, Cleren C, et al. Mice lacking alpha-synuclein are resistant to mitochondrial toxins. Neurobiol Dis. 2006;21:541\u20138.","journal-title":"Neurobiol Dis"},{"key":"7722_CR54","doi-asserted-by":"publisher","first-page":"14524","DOI":"10.1073\/pnas.172514599","volume":"99","author":"W Dauer","year":"2002","unstructured":"Dauer W, Kholodilov N, Vila M, Trillat AC, Goodchild R, Larsen KE, et al. Resistance of alpha-synuclein null mice to the Parkinsonian neurotoxin MPTP. Proc Natl Acad Sci USA. 2002;99:14524\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"7722_CR55","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1002\/mds.21007","volume":"21","author":"O Chiba-Falek","year":"2006","unstructured":"Chiba-Falek O, Lopez GJ, Nussbaum RL. Levels of alpha-synuclein mRNA in sporadic Parkinson's disease patients. Mov Disord. 2006;21:1703\u20138.","journal-title":"Mov Disord"},{"key":"7722_CR56","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1002\/mds.21466","volume":"22","author":"S Papapetropoulos","year":"2007","unstructured":"Papapetropoulos S, Adi N, Mash DC, Shehadeh L, Bishopric N, Shehadeh L. Expression of alpha-synuclein mRNA in Parkinson\u2019s disease. Mov Disord. 2007;22:1057\u20139.","journal-title":"Mov Disord"},{"key":"7722_CR57","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1093\/nar\/gkn084","volume":"36","author":"J Grundemann","year":"2008","unstructured":"Grundemann J, Schlaudraff F, Haeckel O, Liss B. Elevated alpha-synuclein mRNA levels in individual UV-laser-microdissected dopaminergic substantia nigra neurons in idiopathic Parkinson\u2019s disease. Nucleic Acids Res. 2008;36:e38.","journal-title":"Nucleic Acids Res"},{"key":"7722_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2014.166","volume":"5","author":"AK Krug","year":"2014","unstructured":"Krug AK, Gutbier S, Zhao L, Poltl D, Kullmann C, Ivanova V, et al. Transcriptional and metabolic adaptation of human neurons to the mitochondrial toxicant MPP(+). Cell Death Dis. 2014;5:e1222.","journal-title":"Cell Death Dis"},{"key":"7722_CR59","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1007\/s12640-020-00272-3","volume":"38","author":"Z-B Tong","year":"2020","unstructured":"Tong Z-B, Braisted J, Chu P-H, Gerhold D. The MT1G gene in LUHMES neurons is a sensitive biomarker of neurotoxicity. Neurotox Res. 2020;38:967\u201378.","journal-title":"Neurotox Res"},{"key":"7722_CR60","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/nrm2236","volume":"8","author":"F Pampaloni","year":"2007","unstructured":"Pampaloni F, Reynaud EG, Stelzer EHK. The third dimension bridges the gap between cell culture and live tissue. Nat Rev Mol Cell Biol. 2007;8:839\u201345.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"7722_CR61","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2022.836480","volume":"13","author":"A Cacciamali","year":"2022","unstructured":"Cacciamali A, Villa R, Dotti S. 3D cell cultures: evolution of an ancient tool for new applications. Front Physiol. 2022;13:836480.","journal-title":"Front Physiol"},{"key":"7722_CR62","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1007\/s00702-018-1913-1","volume":"125","author":"M Bortolanza","year":"2018","unstructured":"Bortolanza M, Nascimento GC, Socias SB, Ploper D, Cheh\u00edn RN, Raisman-Vozari R, et al. Tetracycline repurposing in neurodegeneration: focus on Parkinson\u2019s disease. J Neural Transm. 2018;125:1403\u201315.","journal-title":"J Neural Transm"},{"key":"7722_CR63","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2021.105256","volume":"151","author":"A Dominguez-Meijide","year":"2021","unstructured":"Dominguez-Meijide A, Parrales V, Vasili E, Gonz\u00e1lez-Liz\u00e1rraga F, K\u00f6nig A, L\u00e1zaro DF, et al. Doxycycline inhibits \u03b1-synuclein-associated pathologies in vitro and in vivo. Neurobiol Dis. 2021;151:105256.","journal-title":"Neurobiol Dis"},{"key":"7722_CR64","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.3390\/cells10051235","volume":"10","author":"M Basu-Shrivastava","year":"2021","unstructured":"Basu-Shrivastava M, Kozoriz A, Desagher S, Lassot I. To Ubiquitinate or not to ubiquitinate: TRIM17 in cell life and death. Cells. 2021;10:1235.","journal-title":"Cells"},{"key":"7722_CR65","doi-asserted-by":"crossref","first-page":"11.23.1","DOI":"10.1002\/cptx.29","volume":"73","author":"G Harris","year":"2017","unstructured":"Harris G, Hogberg H, Hartung T, Smirnova L. 3D Differentiation of LUHMES cell line to study recovery and delayed neurotoxic effects. Curr Protoc Toxicol. 2017;73:11.23.1\u201311.23.28.","journal-title":"Curr Protoc Toxicol"},{"key":"7722_CR66","first-page":"409","volume":"37","author":"M Br\u00fcll","year":"2020","unstructured":"Br\u00fcll M, Spreng A-S, Gutbier S, Loser D, Krebs A, Reich M, et al. Incorporation of stem cell-derived astrocytes into neuronal organoids to allow neuro-glial interactions in toxicological studies. ALTEX. 2020;37:409\u201328.","journal-title":"ALTEX"},{"key":"7722_CR67","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/S0076-6879(06)10019-1","volume":"410","author":"G Lutfalla","year":"2006","unstructured":"Lutfalla G, Uze G. Performing quantitative reverse-transcribed polymerase chain reaction experiments. Meth Enzymol. 2006;410:386\u2013400.","journal-title":"Meth Enzymol"},{"key":"7722_CR68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/gb-2002-3-7-research0034","volume":"3","author":"J Vandesompele","year":"2002","unstructured":"Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002;3:1\u201312.","journal-title":"Genome Biol"},{"key":"7722_CR69","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1038\/nprot.2014.143","volume":"9","author":"LA Volpicelli-Daley","year":"2014","unstructured":"Volpicelli-Daley LA, Luk KC, Lee VM. Addition of exogenous alpha-synuclein preformed fibrils to primary neuronal cultures to seed recruitment of endogenous alpha-synuclein to Lewy body and Lewy neurite-like aggregates. Nat Protoc. 2014;9:2135\u201346.","journal-title":"Nat Protoc"},{"key":"7722_CR70","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1038\/sj.gt.3300938","volume":"6","author":"S Zolotukhin","year":"1999","unstructured":"Zolotukhin S, Byrne BJ, Mason E, Zolotukhin I, Potter M, Chesnut K, et al. Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther. 1999;6:973\u201385.","journal-title":"Gene Ther"},{"key":"7722_CR71","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1089\/hgtb.2014.120","volume":"26","author":"J Piedra","year":"2015","unstructured":"Piedra J, Ontiveros M, Miravet S, Penalva C, Monfar M, Chillon M. Development of a rapid, robust, and universal picogreen-based method to titer adeno-associated vectors. Hum Gene Ther Methods. 2015;26:35\u201342.","journal-title":"Hum Gene Ther Methods"},{"key":"7722_CR72","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/S0076-6879(05)98003-8","volume":"398","author":"G Bossis","year":"2005","unstructured":"Bossis G, Chmielarska K, Gartner U, Pichler A, Stieger E, Melchior F. A fluorescence resonance energy transfer-based assay to study SUMO modification in solution. Methods Enzymol. 2005;398:20\u201332.","journal-title":"Methods Enzymol"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07722-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07722-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07722-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T18:01:49Z","timestamp":1747418509000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07722-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,16]]},"references-count":72,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7722"],"URL":"https:\/\/doi.org\/10.1038\/s41419-025-07722-w","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,16]]},"assertion":[{"value":"25 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All the experimental and surgical procedures were conducted in accordance with the European (Directive 2010\/63\/UE), Spanish (Real Decreto 53\/2013) and Catalan (Decret 214\/97) legislation on the protection of animals used for experimental and other scientific purposes, and approved by the Vall d\u2019Hebron Research Institute (VHIR) Ethical Experimentation Committee to ensure the use of the minimum necessary number of animals and the application of protocols that cause the least pain, suffering or distress to animals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"394"}}